ArticleBMC chemistry2025
Cutting-edge assays for mirabegron and tadalafil combo therapy for benign prostatic hyperplasia; insilico kinetics approach; multi trait sustainability assessment.
Article in BMC chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fourier-based chemometric resolution of the FOLFOX regimen through digital filtering with poly-metric sustainability assessment.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The combination therapy of mirabegron (MIR) and tadalafil (TAD) has gained significant attention in clinical practice for the treatment of Benign Prostatic Hyperplasia as well as overactive bladder syndrome. This study demonstrates the development and validation of two analytical methods for the concurrent determination of tadalafil and mirabegron in their synergistic combo therapy. Spectrophotometry and stability-indicating HPLC were employed for the accurate quantification of both drugs. The spectrophotometric methods were based on derivative, Fourier and ratio derivative of the two drugs, providing simpler, rapid alternatives for routine analysis. The stability-indicating HPLC method was developed using a reverse-phase column with a methanol-phosphate buffer gradient mobile phase, achieving optimal separation with detection at 250 nm for MIR and 225 nm for TAD. Forced degradation studies were performed under acidic, basic, oxidative, neutral, thermal, and photolytic conditions, confirming the method's ability to quantify MIR and TAD in presence of degradation products and establish drug stability. Both techniques were validated based on ICH guidelines, demonstrating excellent linearity, precision, accuracy, and sensitivity. The methods were successfully applied to the analysis of bulk powder and in dosage forms. Both methods were evaluated and found to be environmentally friendly, receiving approval as "green" according to the AGREE (Assessment Tool for Greenness) method, "white" under the RGB12 criteria, and "blue" according to the BAGI (Blue Analytical Greenness Index). These evaluations demonstrate the sustainability and eco-friendliness of the proposed analytical techniques. Furthermore, artificial intelligence was employed through an online tool to ensure that there were no potential drug-drug interactions between MIR and TAD, offering an additional layer of safety in clinical applications. This research contributes to the enhancement of quality control for patients undergoing combination therapy with MIR and TAD and stability testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.